Trial Profile
A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Siremadlin (Primary)
- Indications Acute myeloid leukaemia; Colon cancer; Haematological malignancies; Liposarcoma; Malignant melanoma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cancer; Sarcoma; Solid tumours; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 Dec 2021 Results of exploratory post-hoc analysis of safety and preliminary efficacy in a subset of pts with relapsed AML post SCT and subsequently treated with siremadlin monotherapypresented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 03 Dec 2021 Results assessing recommended dose published in the Clinical Cancer Research
- 04 Aug 2020 Status changed from active, no longer recruiting to completed.